Bio-Site Receives $49.8 Million Cornerstone Investment

Biositu is a high-tech company based on a stable and efficient gene editing technology platform, which integrates model animal customization services, important model animal development and large-scale reproduction and supply, in vivo pharmacology and efficacy evaluation services, and antibody drug R&D outsourcing services. Biopharmaceutical companies. It has a gene editing platform, a model animal reproduction and supply platform, a pharmacology and efficacy platform, and an antibody drug research and development service platform. The company recently received a cornerstone investment of about US$49.8 million. Investors include Chang Bio, Sanjin International, Veken (Hong Kong) Economic and Trade Co., Ltd. (Veken Technology).

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment